Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical

被引：0
|
作者：
West, H. J.
Belt, R. J.
Wakelee, H. A.
Monberg, M. J.
Frye, L. A.
Ye, Z.
Obasaju, C. K.
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Kansas City Canc Ctr, Kansas City, MO USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：393S / 393S
页数：1
相关论文
共 50 条
  • [21] Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).
    Sanborn, Rachel E.
    Duffy, Regan M.
    Fisher, Brenda K.
    Perlewitz, Kelly Shea
    Wallen, Herschel D.
    Li, Rui
    Redmond, William L.
    Koguchi, Yoshinobu
    Fox, Bernard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Koshy, S
    Herbst, RS
    Obasaju, CK
    Fossella, F
    Papadimitrakopoulou, V
    Pisters, KMW
    Blumenschein, G
    Peeples, BO
    Hong, WK
    Zinner, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 634S - 634S
  • [23] Preliminary results of a phase II trial of Docetaxel (D) and Gemcitabine (G) in advanced Non-Small Cell Lung Cancer (NSCLC) in elderly and/or unfit patients (PTS)
    Buffoni, Lucio
    Grillo, Raffaella
    Barone, Carla
    Dongiovanni, Diego
    Gaspari, Fabio
    Giacobino, Alice
    Consito, Lorena
    Ciuffreda, Libero
    Schena, Marina
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S668 - S668
  • [24] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [25] Gemcitabine in locally advanced and metastatic non-small cell lung cancer (NSCLC): The Central European phase II study
    Jassem, J
    Zatloukal, P
    Kanitz, E
    Magyar, P
    Krzakowski, M
    Pawlicki, M
    Petruzelka, L
    Chovan, L
    Pesek, M
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [26] Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Ma, CX
    Nair, S
    Thomas, S
    Mandrekar, SJ
    Nikcevich, DA
    Rowland, KM
    Fitch, TR
    Windschitl, HE
    Hillman, SL
    Schild, SE
    Jett, JR
    Obasaju, C
    Adjei, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5929 - 5937
  • [27] Multi-institutional phase II study of docetaxel (D) and gemcitabine (G) as front-line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Amenedo, M
    Mel, JR
    Casal, J
    Rodriguez, MR
    Aparicio, LA
    Constenla, M
    Lopez, R
    Almanza, C
    Huarte, L
    ANNALS OF ONCOLOGY, 2000, 11 : 112 - 112
  • [28] Phase II randomized trial of single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy
    Gridelli, C
    Reck, M
    Gregorc, V
    Migliorino, M
    Favaretto, A
    Schmittel, A
    Caffo, O
    Blatter, J
    Munoz, M
    Crucitta, E
    Rossi, A
    Koschel, G
    LUNG CANCER, 2005, 49 : S245 - S245
  • [29] Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Barton, John H.
    Patton, Jeffrey F.
    Zubkus, John D.
    Simons, Lisa
    Griner, Paula
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 841 - 845
  • [30] A multicenter phase II study of induction chemotherapy with gemcitabine and carboplatin in patients (pts) with locally advanced non-small cell lung cancer (NSCLC)
    Aerts, J
    van Klaveren, R
    Surmont, V
    Senan, S
    Tan, Y
    Vernhout, R
    van Wijhe, G
    Verhoeven, G
    Hoogsteden, H
    van Meerbeeck, J
    LUNG CANCER, 2005, 49 : S164 - S164
12345